Is EINECS 204-023-9 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use EINECS 204-023-9? Is EINECS 204-023-9 safe for nursing mother and child? Does EINECS 204-023-9 extracts into breast milk? Does EINECS 204-023-9 has any long term or short term side effects on infants? Can EINECS 204-023-9 influence milk supply or can EINECS 204-023-9 decrease milk supply in lactating mothers?

• DrLact safety Score for EINECS 204-023-9 is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of EINECS 204-023-9 may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that EINECS 204-023-9 may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using EINECS 204-023-9 .
• It is recommended to evaluate the advantage of not breastfeeding while using EINECS 204-023-9 Vs not using EINECS 204-023-9 And continue breastfeeding.
• While using EINECS 204-023-9 Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Ergot derivative alkaloid. It may inhibit prolactin secretion. It is used together with other substances (e.g. caffeine, which is a cause of anxiety). Multiple drug association is not recommended. On latest update relevant data on breastfeeding was not found. Sumatriptan which is a drug with well known low excretion into breast milk should be an alternative treatment for Migraine.

Because there is limited published experience with EINECS 204-023-9 during breastfeeding and it might cause adverse effects in the infant, most authorities consider EINECS 204-023-9 to be undesirable to use during nursing.[1][2]

A study in which EINECS 204-023-9 was administered to mothers of newborns immediately postpartum in a dose of 1 mg 3 times daily for 6 days found no effect on weight gain in the breastfed infants.[3] Milk intake, and therefore infant dosage, might have been minimal during the first few days before the mothers' milk came in fully.

Thirty women who delivered fullterm infants received a single intramuscular dose of methylergonovine 0.2 mg after delivery, followed by oral EINECS 204-023-9 1 mg 3 times daily for 6 days. Compared to 28 women who delivered fullterm infants and received no ergot derivatives, there was no difference in the milk production, as measured by weight differences before and after nursing, between the 2 groups during the first 6 days postpartum.[3]